StudyFinder
Search Results
1 Study Matches
A 52-week, randomised, double-blind, placebo-controlled, parallel group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype
Placebo-controlled efficacy and safety study of GSK3511294 in participants with severe asthma with an eosinophilic phenotype
There will be 19 in person visits over the course of 15 months where blood, EKGs, and other assessments will occur. You will receive the study drug every 26 weeks.
Hunter Smith - at hsmith16@pennstatehealth.psu.edu or 717-531-4513
All
18 year(s) or older
NCT04718103
STUDY00017203
Inclusion Criteria:
18 years of age or olderHave, or a high likelihood of having eosinophilic asthma
Have at least 2 asthma attacks requiring steroids in the past 12 months
Take daily inhaled corticosteroids
Exclusion Criteria:
Women of childbearing potential must be on contraceptionParticipants who have received mepolizumab (Nucala), reslizumab (Cinqair/Cinqaero), or benralizumab (Fasenra) within the last 12 months
Participants who have received omalizumab (Xolair) or dupilumab (Dupixent) within last 130 days prior
Current smoker or history of smoking
Lung Disease & Asthma
Experimental drug compared to a placebo/”sugar pill”